A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

NCT03670888 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped The development was stopped due to company's strategy consideration

Conditions

B Cell Lymphoma

Interventions

BIOLOGICAL: JHL1101
BIOLOGICAL: Rituximab

Sponsor

JHL Biotech, Inc.